This review discusses the impact of gene expression profiling and sequencing discoveries on new therapeutic strategies in Non-Hodgkin Lymphomas, particularly Diffuse Large B cell Lymphoma. Alterations in oncogenes, ov...This review discusses the impact of gene expression profiling and sequencing discoveries on new therapeutic strategies in Non-Hodgkin Lymphomas, particularly Diffuse Large B cell Lymphoma. Alterations in oncogenes, over-active signaling pathways down-stream of the B cell receptor, and epigenetic gene mutations will be described. We will also review new targeting strategies aimed at each of these aspects of cell biology encompassing BCL2, BTK, PKCβ, PI3K/mTOR and HDAC inhibition. Specific new drugs in clinical trials and early trial results are included as well.展开更多
文摘This review discusses the impact of gene expression profiling and sequencing discoveries on new therapeutic strategies in Non-Hodgkin Lymphomas, particularly Diffuse Large B cell Lymphoma. Alterations in oncogenes, over-active signaling pathways down-stream of the B cell receptor, and epigenetic gene mutations will be described. We will also review new targeting strategies aimed at each of these aspects of cell biology encompassing BCL2, BTK, PKCβ, PI3K/mTOR and HDAC inhibition. Specific new drugs in clinical trials and early trial results are included as well.
